Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsNewsAboutContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

News

Vortioxetine

(Trintellix®)

Trintellix®

Drug updated on 4/24/2024

Dosage FormTablet (oral; 5 mg, 10 mg, 15 mg, 20 mg)
Drug ClassAntidepressants
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • For the treatment of major depressive disorder (MDD) in adults.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Vortioxetine (Trintellix) is indicated for the treatment of major depressive disorder (MDD) in adults, demonstrating efficacy in improving depressive symptoms and cognitive function across diverse adult populations, including those with specific comorbidities like cardiovascular disease and diabetes.
  • Twenty-three systematic reviews/meta-analyses were reviewed to gather information about vortioxetine's effectiveness and safety profile compared to other treatments for MDD.
  • Compared to other antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), vortioxetine often either matches or surpasses their efficacy in terms of response and remission rates.
  • In terms of tolerability, vortioxetine shows lower rates of adverse events than SNRIs but matches SSRIs; however, gastrointestinal side effects such as nausea are a concern with this drug.
  • Vortioxetine has shown significant benefits on cognitive performance which could be particularly beneficial for elderly populations where cognitive decline is a concurrent concern.
  • While it presents some neurological side effects similar to second-generation antidepressants (SGADs), it also exhibits reduced instances compared to others within its class. It does present gastrointestinal issues akin to other antidepressants though.
  • Vortioxetine appears effective at reducing insomnia and anxiety among patients although comparative efficacy varies across different SGADs.
  • Compared to non-pharmacological treatments like probiotics or cognitive therapies, the study suggests that while these alternatives may have fewer side effects they might not be sufficient for more severe cases where Trintellix performs well.

Product Monograph / Prescribing Information

Document TitleYearSource
Trintellix (vortioxetine) Prescribing Information.2023Takeda Pharmaceuticals America, Deerfield, IL

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis.2024Neuropsychopharmacology Reports
The role of vortioxetine in the treatment of depressive symptoms in general hospital psychiatry: a case-series and Prisma-compliant systematic review of the literature.2024Journal of Clinical Medicine
Probiotics for adults with major depressive disorder compared with antidepressants: a systematic review and network meta-analysis.2024Nutrition Reviews
Effectiveness and safety of vortioxetine for the treatment of major depressive disorder in the real world: a systematic review and meta-analysis.2023International Journal of Neuropyschopharmacology
Εfficacy and safety of vortioxetine (Lu AA21004) in the treatment of adult patients with major depressive disorder: A systematic review and a meta‑analysis of randomized controlled trials.2023Experimental and Therapeutic Medicine
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.2023NPG Open Access
A comprehensive review and meta-analysis of neurological side effects related to second-generation antidepressants in individuals with major depressive disorder.2023Behavioural Brain Research
Systematic review and meta-analysis of vortioxetine for the treatment of major depressive disorder in adults.2022Frontiers in Psychiatry
Effect of vortioxetine on cognitive impairment in patients with major depressive disorder: a systematic review and meta-analysis of randomized controlled trials.2022International Journal of Neuropsychopahrmacology
The incidence and costs of adverse events associated with antidepressants: results from a systematic review, network meta-analysis and multi-country economic model.2022Neuropsychiatric Disease and Treatment
Antidepressants for depressed patients with type 2 diabetes mellitus: A systematic review and network meta-analysis of short-term randomized controlled trials.2022Neuroscience and Biobehavior Reviews
Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness.2022Journal of Affective Disorders
Systematic review of gender bias in vortioxetine clinical trials.2021Progress in Neuro-Psychopharmacology and Biological Psychiatry
Comparative efficacy of pharmacological treatments on measures of self-rated functional outcomes using the Sheehan Disability Scale in patients with major depressive disorder: a systematic review and network meta-analysis.2021CNS Spectrums
Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: a systematic review and meta-analysis.2021Progress in Neuro-Psychopharmacology and Biological Psychiatry
Vortioxetine versus placebo for major depressive disorder: a comprehensive analysis of the clinical trial dataset.2021Journal of Clinical Psychiatry
Cognitive effects of vortioxetine in older adults: a systematic review.2021Therapeutic Advances in Psychopharmacology
New generation antidepressants for depression in children and adolescents: a network meta-analysis.2021The Cochrane Database of Systematic Reviews
Procognitive effects of antidepressants and other therapeutic agents in major depressive disorder: a systematic review.2020Journal of Clinical Psychiatry
Comparative remission rates and tolerability of drugs for generalised anxiety disorder: a systematic review and network meta-analysis of double-blind randomized controlled trials.2020Frontiers in Pharmacology
Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: a systematic review, pairwise and network meta-analysis.2019European Neuropsychopharmacology
The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis.2019African Health Sciences
Pharmacological and non-pharmacological treatments for major depressive disorder in adults: A systematic review and network meta-analysis.2019Psychiatry Research

Clinical Practice Guidelines

Document TitleYearSource
Nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder: a living clinical guideline from the American College of Physicians.2023Annals of Internal Medicine
VA/DoD clinical practice guideline for the management of major depressive disorder. 2022Department of Veterans Affairs: Department of Defense
The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. 2020Australian & New Zealand Journal of Psychiatry